<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00092534</url>
  </required_header>
  <id_info>
    <org_study_id>V501-015</org_study_id>
    <secondary_id>2004_082</secondary_id>
    <nct_id>NCT00092534</nct_id>
  </id_info>
  <brief_title>Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015)</brief_title>
  <official_title>A Randomized, Worldwide, Placebo-Controlled, Double-Blind Study to Investigate the Safety Immunogenicity and Efficacy on the Incidence of HPV 16/18-Related CIN2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18,) L1 Virus-Like Particle (VLP) Vaccine (V501, Gardasil) in 16- to 23-Year Old Women - The F.U.T.U.R.E. II Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to determine if Gardasil (V501) an investigational
      vaccine with 4 components is able to prevent cervical cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The original base study (V501-015) (NCT00092534) was extended in protocol V501-015-10.
      Subjects in the placebo arm of the base study were given 3 doses of open-label GARDASIL™
      (V501) at Extension (EXT) Day 1, EXT Month 2 and EXT Month 6 and were followed to EXT Month
      7. Subjects who received only 1 dose of GARDASIL™ in the base study were given 3 doses of
      open-label GARDASIL™ (V501) at Extension (EXT) Day 1, EXT Month 2 and EXT Month 6 and were
      followed to EXT Month 7. Subjects who received 2 doses of GARDASIL™ in the base study were
      given only 1 dose of GARDASIL™ at EXT Day 1 and were followed for 15 days (day of vaccination
      plus 14 days).

      A second extension study, V501-015-20, will assess the effectiveness, immunogenicity and
      safety of GARDASIL™ during a period of 10-14 years following completion of the base study
      (V501-015) or the V501-015-10 extension. Subjects from Denmark, Iceland, Norway and Sweden
      who participated in the base study were eligible to enroll. Effectiveness and safety will be
      assessed by registry-based follow-up. Immunogenicity will be assessed by serological testing
      at approximately Year 5 and Year 10 of the V501-015-20 extension, respectively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2002</start_date>
  <completion_date type="Actual">March 31, 2017</completion_date>
  <primary_completion_date type="Actual">July 31, 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability; Incidence of the Composite Endpoint of HPV 16 or HPV 18 Related CIN2/3 or Invasive Cervical Carcinoma After Completion of the Vaccination Series for Relevant HPV Type</measure>
    <time_frame>Follow-up through end of study (4 years)</time_frame>
    <description>Tolerability = Number of subjected affected. Incidence Rate per person-years of follow-up.
The tolerability objective was to demonstrate that Gardasil is generally well tolerated by females aged 16-23. The relevant data are presented in the Reported Adverse Events section. No formal statistical hypothesis testing were performed for this objective.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects With Anti-HPV 6 Titer &gt;/= 20 mMU/mL</measure>
    <time_frame>Week 4 Postdose 3 (4 weeks after 3rd vaccine dose)</time_frame>
    <description>Subsequent to protocol registration, an updated serology assay was used in which seropositivity was defined as &gt;/= 20 mMU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Anti-HPV 11 Titer &gt;/= 16 mMU/mL</measure>
    <time_frame>Week 4 Postdose 3</time_frame>
    <description>Subsequent to protocol registration, an updated serology assay was used in which seropositivity was defined as &gt;/= 16 mMU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Anti-HPV 16 Titer &gt;/= 20 mMU/mL</measure>
    <time_frame>Week 4 Postdose 3</time_frame>
    <description>Subsequent to protocol registration, an updated serology assay was used in which seropositivity was defined as &gt;/= 20mMU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With Anti-HPV 18 Titer &gt;/= 24 mMU/mL</measure>
    <time_frame>Week 4 Postdose 3</time_frame>
    <description>Subsequent to protocol registration, an updated serology assay was used in which seropositivity was defined as &gt;/= 24 mMU/mL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12167</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Genital Warts</condition>
  <arm_group>
    <arm_group_label>Quadrivalent Human Papillomavirus (HPV) Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine</intervention_name>
    <description>Duration of Treatment: 6 months</description>
    <arm_group_label>Quadrivalent Human Papillomavirus (HPV) Vaccine</arm_group_label>
    <other_name>V501</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Matching Placebo to Quadrivalent Human Papillomavirus Vaccine</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women with an intact uterus with lifetime history of 0-4 sexual partners

             --For Extension Phase:

          -  Subject received placebo or an incomplete vaccination series in the original study

        Exclusion Criteria:

          -  Prior Human Papilloma Virus (HPV) vaccination

          -  Prior abnormal Paps

          -  Prior history of genital warts

             --For Extension Phase:

          -  Prior complete HPV vaccination series

          -  Subject lives in a country in which Gardasil is approved and is within the age range
             of the local labeling for Gardasil
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>23 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007 May 10;356(19):1915-27.</citation>
    <PMID>17494925</PMID>
  </reference>
  <reference>
    <citation>Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, Barr E, Haupt RM, Joura EA. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009 Mar 15;199(6):805-14. doi: 10.1086/597071.</citation>
    <PMID>19199546</PMID>
  </reference>
  <reference>
    <citation>Barr E, Gause CK, Bautista OM, Railkar RA, Lupinacci LC, Insinga RP, Sings HL, Haupt RM. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. Am J Obstet Gynecol. 2008 Mar;198(3):261.e1-11. doi: 10.1016/j.ajog.2007.09.001.</citation>
    <PMID>18313445</PMID>
  </reference>
  <reference>
    <citation>Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, Steben M, Jones RW, Bryan J, Taddeo FJ, Bautista OM, Esser MT, Sings HL, Nelson M, Boslego JW, Sattler C, Barr E, Paavonen J. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007 May 19;369(9574):1693-702.</citation>
    <PMID>17512854</PMID>
  </reference>
  <reference>
    <citation>Perez G, Lazcano-Ponce E, Hernandez-Avila M, García PJ, Muñoz N, Villa LL, Bryan J, Taddeo FJ, Lu S, Esser MT, Vuocolo S, Sattler C, Barr E. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer. 2008 Mar 15;122(6):1311-8.</citation>
    <PMID>18000825</PMID>
  </reference>
  <reference>
    <citation>FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis. 2007 Nov 15;196(10):1438-46. Epub 2007 Oct 31.</citation>
    <PMID>18008221</PMID>
  </reference>
  <reference>
    <citation>Ault KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007 Jun 2;369(9576):1861-8.</citation>
    <PMID>17544766</PMID>
  </reference>
  <reference>
    <citation>Giuliano AR, Lazcano-Ponce E, Villa L, Nolan T, Marchant C, Radley D, Golm G, McCarroll K, Yu J, Esser MT, Vuocolo SC, Barr E. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis. 2007 Oct 15;196(8):1153-62. Epub 2007 Sep 17.</citation>
    <PMID>17955433</PMID>
  </reference>
  <reference>
    <citation>Garland SM, Insinga RP, Sings HL, Haupt RM, Joura EA. Human papillomavirus infections and vulvar disease development. Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1777-84. doi: 10.1158/1055-9965.EPI-09-0067.</citation>
    <PMID>19505910</PMID>
  </reference>
  <reference>
    <citation>Skjeldestad FE, Mehta V, Sings HL, Øvreness T, Turpin J, Su L, Boerckel P, Roberts C, Bryan J, Jansen KU, Esser MT, Liaw KL. Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics. Acta Obstet Gynecol Scand. 2008;87(1):81-8.</citation>
    <PMID>17943470</PMID>
  </reference>
  <reference>
    <citation>Nygård M, Saah A, Munk C, Tryggvadottir L, Enerly E, Hortlund M, Sigurdardottir LG, Vuocolo S, Kjaer SK, Dillner J. Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine. Clin Vaccine Immunol. 2015 Aug;22(8):943-8. doi: 10.1128/CVI.00133-15. Epub 2015 Jun 17.</citation>
    <PMID>26084514</PMID>
  </reference>
  <results_reference>
    <citation>Kjaer SK, Nygård M, Dillner J, Brooke Marshall J, Radley D, Li M, Munk C, Hansen BT, Sigurdardottir LG, Hortlund M, Tryggvadottir L, Joshi A, Das R, Saah AJ. A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries. Clin Infect Dis. 2018 Jan 18;66(3):339-345. doi: 10.1093/cid/cix797.</citation>
    <PMID>29029053</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2004</study_first_submitted>
  <study_first_submitted_qc>September 27, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2004</study_first_posted>
  <results_first_submitted>July 20, 2009</results_first_submitted>
  <results_first_submitted_qc>October 15, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2009</results_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Quadrivalent Human Papillomavirus Vaccine (Group 1)</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Group 2)</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
        </group>
        <group group_id="P3">
          <title>Extension Study</title>
          <description>This group includes 581 subjects who received placebo during the base study, (Group 2-Base Study) and 13 additional subjects who were randomized to the active vaccine arm of the base study (from Group 1-Base Study), but received fewer than the full three doses of Quadrivalent HPV vaccine during the base study. Subjects designated as &quot;Completed Period&quot; are those who received three doses of Quadrivalent HPV vaccine and completed all required follow-up visits. Subjects designated as &quot;Not Completed&quot; are those who: a) Received all three vaccinations, but did not complete follow-up; b) Did not receive all vaccinations, but completed follow-up, or c) Did not receive all vaccinations, and did not complete follow-up.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Base Study Vaccination Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6087"/>
                <participants group_id="P2" count="6080"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5916"/>
                <participants group_id="P2" count="5954"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="126"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized not Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>New Medical History (Not AEs)</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Travel</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Closed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Base Study Follow Up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5942">Includes subjects who did not receive 3 doses of vaccine/placebo but continued into the follow-up.</participants>
                <participants group_id="P2" count="5971">Includes subjects who did not receive 3 doses of vaccine/placebo but continued into the follow-up.</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5626"/>
                <participants group_id="P2" count="5277"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="316"/>
                <participants group_id="P2" count="694"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="146"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Travel</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Closed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subjects continuing</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subjects in extension</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="371"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="594"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="449"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="145"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Travel</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Closed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Ended</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Quadrivalent Human Papillomavirus Vaccine (Group 1)</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Group 2)</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6087"/>
            <count group_id="B2" value="6080"/>
            <count group_id="B3" value="12167"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.0" spread="2.2"/>
                    <measurement group_id="B2" value="19.9" spread="2.1"/>
                    <measurement group_id="B3" value="19.9" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>Age for study subjects was recorded at the time of subject entry into the base study.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 15 and 26 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6087"/>
                    <measurement group_id="B2" value="6080"/>
                    <measurement group_id="B3" value="12167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6087"/>
                    <measurement group_id="B2" value="6080"/>
                    <measurement group_id="B3" value="12167"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <description>Subject race was determined at subject entry into the base study.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="227"/>
                    <measurement group_id="B3" value="398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="555"/>
                    <measurement group_id="B2" value="557"/>
                    <measurement group_id="B3" value="1112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4584"/>
                    <measurement group_id="B2" value="4550"/>
                    <measurement group_id="B3" value="9134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other-Unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="625"/>
                    <measurement group_id="B2" value="610"/>
                    <measurement group_id="B3" value="1235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tolerability; Incidence of the Composite Endpoint of HPV 16 or HPV 18 Related CIN2/3 or Invasive Cervical Carcinoma After Completion of the Vaccination Series for Relevant HPV Type</title>
        <description>Tolerability = Number of subjected affected. Incidence Rate per person-years of follow-up.
The tolerability objective was to demonstrate that Gardasil is generally well tolerated by females aged 16-23. The relevant data are presented in the Reported Adverse Events section. No formal statistical hypothesis testing were performed for this objective.</description>
        <time_frame>Follow-up through end of study (4 years)</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant type at Day 1 and Polymerase chain reaction (PCR) negative to the relevant type through Month 7, and must provide follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Human Papillomavirus Vaccine (Group 1)</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Group 2)</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability; Incidence of the Composite Endpoint of HPV 16 or HPV 18 Related CIN2/3 or Invasive Cervical Carcinoma After Completion of the Vaccination Series for Relevant HPV Type</title>
          <description>Tolerability = Number of subjected affected. Incidence Rate per person-years of follow-up.
The tolerability objective was to demonstrate that Gardasil is generally well tolerated by females aged 16-23. The relevant data are presented in the Reported Adverse Events section. No formal statistical hypothesis testing were performed for this objective.</description>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant type at Day 1 and Polymerase chain reaction (PCR) negative to the relevant type through Month 7, and must provide follow-up data.</population>
          <units>Incidence per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5306"/>
                <count group_id="O2" value="5262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent relative risk reduction</param_type>
            <param_value>96.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>88.2</ci_lower_limit>
            <ci_upper_limit>99.6</ci_upper_limit>
            <estimate_desc>Confidence Interval (CI) based on binomial tail probabilities and not from a dispersion parameter</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Anti-HPV 6 Titer &gt;/= 20 mMU/mL</title>
        <description>Subsequent to protocol registration, an updated serology assay was used in which seropositivity was defined as &gt;/= 20 mMU/mL</description>
        <time_frame>Week 4 Postdose 3 (4 weeks after 3rd vaccine dose)</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant type at Day 1 and PCR negative to the relevant type through Month 7, and must provide data. Only subjects participating in a substudy had blood samples at Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Human Papillomavirus Vaccine (Group 1)</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Group 2)</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Anti-HPV 6 Titer &gt;/= 20 mMU/mL</title>
          <description>Subsequent to protocol registration, an updated serology assay was used in which seropositivity was defined as &gt;/= 20 mMU/mL</description>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant type at Day 1 and PCR negative to the relevant type through Month 7, and must provide data. Only subjects participating in a substudy had blood samples at Month 7.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1056"/>
                <count group_id="O2" value="1057"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1054"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Anti-HPV 11 Titer &gt;/= 16 mMU/mL</title>
        <description>Subsequent to protocol registration, an updated serology assay was used in which seropositivity was defined as &gt;/= 16 mMU/mL</description>
        <time_frame>Week 4 Postdose 3</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant type at Day 1 and PCR negative to the relevant type through Month 7, and must provide data. Only subjects participating in a substudy had blood samples at Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Human Papillomavirus Vaccine (Group 1)</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Group 2)</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Anti-HPV 11 Titer &gt;/= 16 mMU/mL</title>
          <description>Subsequent to protocol registration, an updated serology assay was used in which seropositivity was defined as &gt;/= 16 mMU/mL</description>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant type at Day 1 and PCR negative to the relevant type through Month 7, and must provide data. Only subjects participating in a substudy had blood samples at Month 7.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1057"/>
                <count group_id="O2" value="1057"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1054"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Anti-HPV 16 Titer &gt;/= 20 mMU/mL</title>
        <description>Subsequent to protocol registration, an updated serology assay was used in which seropositivity was defined as &gt;/= 20mMU/mL</description>
        <time_frame>Week 4 Postdose 3</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant type at Day 1 and PCR negative to the relevant type through Month 7, and must provide data. Only subjects participating in a substudy had blood samples at Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Human Papillomavirus Vaccine (Group 1)</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Group 2)</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Anti-HPV 16 Titer &gt;/= 20 mMU/mL</title>
          <description>Subsequent to protocol registration, an updated serology assay was used in which seropositivity was defined as &gt;/= 20mMU/mL</description>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant type at Day 1 and PCR negative to the relevant type through Month 7, and must provide data. Only subjects participating in a substudy had blood samples at Month 7.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1017"/>
                <count group_id="O2" value="994"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1014"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Anti-HPV 18 Titer &gt;/= 24 mMU/mL</title>
        <description>Subsequent to protocol registration, an updated serology assay was used in which seropositivity was defined as &gt;/= 24 mMU/mL</description>
        <time_frame>Week 4 Postdose 3</time_frame>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant type at Day 1 and PCR negative to the relevant type through Month 7, and must provide data. Only subjects participating in a substudy had blood samples at Month 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Human Papillomavirus Vaccine (Group 1)</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Group 2)</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Anti-HPV 18 Titer &gt;/= 24 mMU/mL</title>
          <description>Subsequent to protocol registration, an updated serology assay was used in which seropositivity was defined as &gt;/= 24 mMU/mL</description>
          <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant type at Day 1 and PCR negative to the relevant type through Month 7, and must provide data. Only subjects participating in a substudy had blood samples at Month 7.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1140"/>
                <count group_id="O2" value="1119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1133"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Number of subjects at risk included randomized subjects who had follow-up. Differing numbers of subjects were at risk for serious vs. other adverse experiences (AEs) as both serious and non-serious AEs were collected in the base period and only serious AEs were collected in the extension period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Quadrivalent Human Papillomavirus Vaccine (Group 1)</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 1 were vaccinated (at Day 1, Month 2 and Month 6) with the Quadrivalent HPV vaccine.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received the Quadrivalent HPV vaccine; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Group 2)</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time study subjects in Group 2 were vaccinated (at Day 1, Month 2 and Month 6) with placebo.
The Follow-up Period for the Base Study encompassed the follow-up of subjects who had received placebo; from completion of the Vaccination Period at Month 7 through Month 48 of the study.</description>
        </group>
        <group group_id="E3">
          <title>Extension Study</title>
          <description>This group includes 581 subjects who received placebo during the base study, (Group 2-Base Study) and 13 additional subjects who were randomized to the active vaccine arm of the base study (from Group 1-Base Study), but received fewer than the full three doses of Quadrivalent HPV vaccine during the base study. Subjects designated as &quot;Completed Period&quot; are those who received three doses of Quadrivalent HPV vaccine and completed all required follow-up visits. Subjects designated as &quot;Not Completed&quot; are those who: a) Received all three vaccinations, but did not complete follow-up; b) Did not receive all vaccinations, but completed follow-up, or c) Did not receive all vaccinations, and did not complete follow-up.
Extension study includes subjects from Group 2-Base Study who were vaccinated with quadrivalent HPV vaccine.
No data on non-serious adverse events were collected on this group during the extension study, hence no data are entered for them in the table.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46"/>
                <counts group_id="E2" subjects_affected="56"/>
                <counts group_id="E3" subjects_affected="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Injection site joint movement impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hypersensitivty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Infective thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pelvic Inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Uterine infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Failed forceps delivery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Breech presentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Brow presentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cephalo-pelvic disproportion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cervix dystocia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Failed trial of labour</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Foetal distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Foetal malpresentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Imminent abortion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Oligohydramnios</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pregnancy induced hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Prolonged pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Uterine contractions during pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Cervical incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervix haemorrhage uterine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Vaginal laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Vulvovaginal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Neonatal asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cutaneous vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6021"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6033"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="594"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="551"/>
                <counts group_id="E2" subjects_affected="499"/>
                <counts group_id="E3" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="6019"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="6031"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="503" subjects_at_risk="6019"/>
                <counts group_id="E2" subjects_affected="433" subjects_at_risk="6031"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="6019"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="6031"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="162" subjects_at_risk="6019"/>
                <counts group_id="E2" subjects_affected="167" subjects_at_risk="6031"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive Vice President, Clinical and Quantitative Sciences</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

